Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Orexo AB (publ) is a Swedish specialty pharmaceutical company that develops and commercializes pharmaceuticals and digital therapies primarily in the United States, European Union, United Kingdom, and internationally. The company focuses on treatments for opioid use disorder with products such as Zubsolv tablets, alongside Abstral for breakthrough cancer pain and Edluar for insomnia. Its digital therapies include deprexis for depression, vorvida for alcohol management, and modia for opioid use disorder support. Orexo AB (publ) leverages proprietary drug delivery technologies like AmorphOX, a powder-based platform that enhances bioavailability and stability for small and large molecules, enabling innovative administration methods such as nasal delivery. This technology supports a pipeline addressing opioid overdose with OX124 and OX125, anaphylaxis via OX640, and endometriosis with OX-MPI. The company also pursues collaborations, including with Abera Bioscience for nasal powder vaccines. Specializing in severe diseases and rescue medications, Orexo AB (publ) operates a US subsidiary for commercialization and partners globally for development and distribution. Founded in 1994 and headquartered in Uppsala, Sweden, it plays a key role in addressing unmet needs in addiction treatment and emergency care within the healthcare sector.
kr 1.99
+kr 0.01 (+0.30%)
Live · 11:02 PM · Twelve Data
The business is unprofitable at the operating level (-1310.00% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 12.5% YoY. The question is whether this is cyclical or a structural shift.
Negative free cash flow of -kr 195M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
-kr 115M
▼ -12.5% YoY
Net Income (TTM)
kr 521M
▲ +414.9% YoY
Op. Margin
356.16%
▲ +147.9pp YoY
ROIC
-36.91%
▲ +30.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 262M
▲ +41.0% YoY
Op. Cash Flow (TTM)
kr 10M
▲ +123.1% YoY
Net Debt
-kr 421M
Net Cash Position
Cash & Equiv.
kr 912M
3Y CAGR: -65.3%
Continue Research
Orexo AB (publ) (ORX.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Orexo AB (publ) scores 25/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Orexo AB (publ) scores 25 out of 100 on Intrinsiqq's quality score, a weighted blend of 5 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 356.2% operating margin and a -36.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh ORX.XSTO's valuation and scores 25/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.